CPXX - Kevrklar
I don't have a good handle on where the stock should trade on a DCF, I have not built a model, but company expects 400M world wide sales for secondary AML, my assumption is there will be a lot of off label use for somewhat obvious reasons. AML is also only treated in a narrow group of hospitals around the country so depending on data the sales effort should not required a large sales & marketing budget.
The results may also validate their platform. Looking forward to tomorrows call. Will need to ultimately see the full data set.
Glad you had a few shares, rare to have a 350% gain in bioland these days. good luck with your trading...
-BioHunter
News 
Market Data 
Discover 
